Review





Similar Products

apoptosis analysis kit  (Beyotime)
99
Beyotime apoptosis analysis kit
Apoptosis Analysis Kit, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c1052/Cell+Cycle+and+Apoptosis+Analysis+Kit/pmc12963922-464-3-6
Average 99 stars, based on 1 article reviews
apoptosis analysis kit - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
cell cycle and apoptosis analysis kit  (Beyotime)
99
Beyotime cell cycle and apoptosis analysis kit
Broad-spectrum antitumor activity of B6ADC (A) Tumor suppression efficacy of B6ADC in multiple pancreatic cancer CDX models ( n = 5∼7/group). (B) Tumor suppression efficacy of B6ADC in four cell lines with varying TROP2/c-Met expression levels ( n = 5∼7/group). Scale bar, 50 μm. (C) Tumor suppression effect of a single 2.2 mg/kg dose of B6ADC in SPC-A1 lung adenocarcinoma-bearing mice with a tumor volume of 1,200 mm 3 ( n = 5∼7/group). (D) Comparison of tumor suppression between B6ADC and the combination of parental “TROP2ADC and c-MetADC” in SPC-A1 tumor-bearing mice (initial tumor volume: 600 mm 3 ) ( n = 6/group). See also . (E) Comparison of tumor suppression between B6ADC and the combination of “marketed TROP2ADC (SG) and marketed c-MetADC (Teliso-V)” in SPC-A1 tumor-bearing mice (initial tumor volume: 600 mm 3 ) ( n = 5∼7/group). See also . (F) Transmission electron microscopy images showing <t>apoptosis</t> in BxPC-3 tumors on day 7 after treatment with B6ADC and the control. Apoptotic features (e.g., chromatin condensation and nuclear fragmentation) were observed in the B6ADC-treated group ( n = 3 independent experiments). Scale bar, 2 μm. See also . Statistical analysis was performed using two-way ANOVA. The data are presented as the means ± SDs. ∗ p < 0.05, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001, and p > 0.05 (no significance, ns).
Cell Cycle And Apoptosis Analysis Kit, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c1052/Cell+Cycle+and+Apoptosis+Analysis+Kit/pmc13130678-51-0-7
Average 99 stars, based on 1 article reviews
cell cycle and apoptosis analysis kit - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
beyotime cell cycle  (Beyotime)
99
Beyotime beyotime cell cycle
Broad-spectrum antitumor activity of B6ADC (A) Tumor suppression efficacy of B6ADC in multiple pancreatic cancer CDX models ( n = 5∼7/group). (B) Tumor suppression efficacy of B6ADC in four cell lines with varying TROP2/c-Met expression levels ( n = 5∼7/group). Scale bar, 50 μm. (C) Tumor suppression effect of a single 2.2 mg/kg dose of B6ADC in SPC-A1 lung adenocarcinoma-bearing mice with a tumor volume of 1,200 mm 3 ( n = 5∼7/group). (D) Comparison of tumor suppression between B6ADC and the combination of parental “TROP2ADC and c-MetADC” in SPC-A1 tumor-bearing mice (initial tumor volume: 600 mm 3 ) ( n = 6/group). See also . (E) Comparison of tumor suppression between B6ADC and the combination of “marketed TROP2ADC (SG) and marketed c-MetADC (Teliso-V)” in SPC-A1 tumor-bearing mice (initial tumor volume: 600 mm 3 ) ( n = 5∼7/group). See also . (F) Transmission electron microscopy images showing <t>apoptosis</t> in BxPC-3 tumors on day 7 after treatment with B6ADC and the control. Apoptotic features (e.g., chromatin condensation and nuclear fragmentation) were observed in the B6ADC-treated group ( n = 3 independent experiments). Scale bar, 2 μm. See also . Statistical analysis was performed using two-way ANOVA. The data are presented as the means ± SDs. ∗ p < 0.05, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001, and p > 0.05 (no significance, ns).
Beyotime Cell Cycle, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c1052/Cell+Cycle+and+Apoptosis+Analysis+Kit/pm42002125-251-5-5
Average 99 stars, based on 1 article reviews
beyotime cell cycle - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier

Image Search Results


Broad-spectrum antitumor activity of B6ADC (A) Tumor suppression efficacy of B6ADC in multiple pancreatic cancer CDX models ( n = 5∼7/group). (B) Tumor suppression efficacy of B6ADC in four cell lines with varying TROP2/c-Met expression levels ( n = 5∼7/group). Scale bar, 50 μm. (C) Tumor suppression effect of a single 2.2 mg/kg dose of B6ADC in SPC-A1 lung adenocarcinoma-bearing mice with a tumor volume of 1,200 mm 3 ( n = 5∼7/group). (D) Comparison of tumor suppression between B6ADC and the combination of parental “TROP2ADC and c-MetADC” in SPC-A1 tumor-bearing mice (initial tumor volume: 600 mm 3 ) ( n = 6/group). See also . (E) Comparison of tumor suppression between B6ADC and the combination of “marketed TROP2ADC (SG) and marketed c-MetADC (Teliso-V)” in SPC-A1 tumor-bearing mice (initial tumor volume: 600 mm 3 ) ( n = 5∼7/group). See also . (F) Transmission electron microscopy images showing apoptosis in BxPC-3 tumors on day 7 after treatment with B6ADC and the control. Apoptotic features (e.g., chromatin condensation and nuclear fragmentation) were observed in the B6ADC-treated group ( n = 3 independent experiments). Scale bar, 2 μm. See also . Statistical analysis was performed using two-way ANOVA. The data are presented as the means ± SDs. ∗ p < 0.05, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001, and p > 0.05 (no significance, ns).

Journal: Cell Reports Medicine

Article Title: A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer

doi: 10.1016/j.xcrm.2026.102688

Figure Lengend Snippet: Broad-spectrum antitumor activity of B6ADC (A) Tumor suppression efficacy of B6ADC in multiple pancreatic cancer CDX models ( n = 5∼7/group). (B) Tumor suppression efficacy of B6ADC in four cell lines with varying TROP2/c-Met expression levels ( n = 5∼7/group). Scale bar, 50 μm. (C) Tumor suppression effect of a single 2.2 mg/kg dose of B6ADC in SPC-A1 lung adenocarcinoma-bearing mice with a tumor volume of 1,200 mm 3 ( n = 5∼7/group). (D) Comparison of tumor suppression between B6ADC and the combination of parental “TROP2ADC and c-MetADC” in SPC-A1 tumor-bearing mice (initial tumor volume: 600 mm 3 ) ( n = 6/group). See also . (E) Comparison of tumor suppression between B6ADC and the combination of “marketed TROP2ADC (SG) and marketed c-MetADC (Teliso-V)” in SPC-A1 tumor-bearing mice (initial tumor volume: 600 mm 3 ) ( n = 5∼7/group). See also . (F) Transmission electron microscopy images showing apoptosis in BxPC-3 tumors on day 7 after treatment with B6ADC and the control. Apoptotic features (e.g., chromatin condensation and nuclear fragmentation) were observed in the B6ADC-treated group ( n = 3 independent experiments). Scale bar, 2 μm. See also . Statistical analysis was performed using two-way ANOVA. The data are presented as the means ± SDs. ∗ p < 0.05, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001, and p > 0.05 (no significance, ns).

Article Snippet: Cell Cycle and Apoptosis Analysis Kit , BEYOTIME , Cat#C1052.

Techniques: Activity Assay, Expressing, Comparison, Transmission Assay, Electron Microscopy, Control